Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort

• Published in: Frontiers in immunology Vol. 12; p. 741369
• Main Authors: Hu, Chaojun, Li, Siting, Xie, Zhijuan, You, Hanxiao, Jiang, Hui, Shi, Yu, Qi, Wanting, Zhao, Jiuliang, Wang, Qian, Tian, Xinping, Li, Mengtao, Zhao, Yan, Zeng, Xiaofeng
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 10.09.2021
• Subjects: Adult; Annexin A5 - immunology; anti-annexin V; anti-phosphatidylserine/prothrombin; Antibodies, Antiphospholipid - blood; antiphospholipid antibodies; antiphospholipid syndrome; Antiphospholipid Syndrome - diagnosis; Autoantibodies - blood; beta 2-Glycoprotein I - immunology; Cardiolipins - immunology; China; Cohort Studies; Female; Humans; immunoglobulin A; Immunology; Male; Middle Aged; Phosphatidylserines - immunology; Predictive Value of Tests; Prospective Studies; Risk; Young Adult; China; antiphospholipid syndrome; immunoglobulin A; anti-annexin V; anti-phosphatidylserine/prothrombin; antiphospholipid antibodies
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.741369

Although specific anti-phospholipid antibodies (aPLs) have been used in the diagnosis of the antiphospholipid syndrome (APS) for years, new biomarkers are required to increase its diagnostic and risk-predictive power. This study aimed to explore the value of several non-criteria aPLs in a Chinese cohort. A total of 312 subjects, namely, 100 patients diagnosed with primary APS, 51 with APS secondary to SLE, 71 with SLE, and 90 healthy controls, were recruited. Serum anticardiolipin (aCL) IgG/IgM/IgA, anti-β2-glycoprotein I (aβ2GPI) IgG/IgM/IgA, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) IgG/IgM, and anti-annexin A5 antibodies (aAnxV) IgG/IgM were tested using ELISA kits. Of the total number of patients, 30.46% and 6.62% with APS were positive for aCL or aβ2GPI IgA, respectively, while 39.07% and 24.50% were positive for aAnxV or aPS/PT for at least one antibody (IgG or IgM). The addition test of aCL IgA and aAnxV IgM assists in identifying seronegative APS patients, and IgG aPS/PT was linked to stroke. Detection of aCL IgA, aβ2GPI IgA, aAnxV IgG/M, and aPS/PT IgG/M as a biomarker provides additive value in APS diagnosis and would help in risk prediction for APS patients in medical practice.